Nuclear Medicine at Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa.
Nuclear Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Curr Pharm Des. 2018;24(7):772-786. doi: 10.2174/1381612823666171122111558.
Infectious diseases remain a major health problem and cause of death worldwide. It is expected that the socio-economic impact will further intensify due to escalating resistance to antibiotics, an ageing population and an increase in the number of patients under immunosuppressive therapy and implanted medical devices. Even though radiolabeled probes and leukocytes are routinely used in clinical practice, it might still be difficult to distinguish sterile inflammation from inflammation caused by bacteria. Moreover, the majority of these probes are based on the attraction of leukocytes which may be hampered in neutropenic patients. Novel approaches that can be implemented in clinical practice and allow for swift diagnosis of infection by targeting the microorganism directly, are posing an attractive strategy. Here we review the current strategies to directly image bacteria using radionuclides and we provide an overview of the preclinical efforts to develop and validate new approaches. Indeed, significant progress has been made in the past years, but very few radiopharmaceuticals (that were promising in preclinical studies) have made it into clinical practice. We will discuss the challenges that remain to select good candidates for imaging agents targeting bacteria.
传染病仍然是全球主要的健康问题和死亡原因。预计由于抗生素耐药性的不断升级、人口老龄化以及接受免疫抑制治疗和植入医疗器械的患者数量增加,其社会经济影响将进一步加剧。尽管放射性标记探针和白细胞在临床实践中常规使用,但仍难以区分无菌性炎症和由细菌引起的炎症。此外,这些探针中的大多数都是基于白细胞的吸引力,而中性粒细胞减少症患者可能会受到阻碍。直接针对微生物的新方法,可以在临床实践中实施,并能够迅速诊断感染,这是一种很有吸引力的策略。在这里,我们回顾了使用放射性核素直接对细菌成像的现有策略,并概述了开发和验证新方法的临床前努力。事实上,过去几年已经取得了重大进展,但很少有放射性药物(在临床前研究中很有前途)真正进入临床实践。我们将讨论在选择针对细菌的成像剂的良好候选物方面仍然存在的挑战。